Migraine News and Research

Latest Migraine News and Research

Study indicates ocular shingles may increase stroke risk

Having a shingles infection that affects the eyes may increase the risk of stroke, according to new research published in the March 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

MAP Pharmaceuticals announces net loss of $13.4M for fourth-quarter 2009

MAP Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

BDSI provides update on product portfolio, key upcoming milestones

BioDelivery Sciences International, Inc. today provided a summary of its business overview webcast that was conducted on Thursday, February 25, 2010. Dr. Mark A. Sirgo, President and Chief Executive Officer, and Dr. Andrew L. Finn, Executive Vice President of Product Development, provided an update on the product portfolio, including development plans, anticipated timelines, and key upcoming milestones.

28 Feb 2010

Paralysis from a stroke: Rare nerve transfer improves mobility

The Plastic Surgery Center today announced the successful results of a rare nerve transfer performed for the first known time on a stroke patient to reverse paralysis. Following the procedure, which was led by Dr. Andrew Elkwood, M.D., 47-year old Vincent Filipini is now able to lift, move and bend his once paralyzed arm. Mr. Filipini continues to show improvement in his mobility.

26 Feb 2010

University of California researchers awarded AAN's 2010 Potamkin Prize

The American Academy of Neurology (AAN) is awarding its 2010 Potamkin Prize to two researchers for their work in Alzheimer's disease and frontotemporal lobar degeneration (FTLD), a common type of dementia. Bruce L. Miller, MD, and Lennart Mucke, MD, both of the University of California San Francisco will receive the Award during the AAN's 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists with more than 2,000 presentations made on the latest advances in neurologic research.

19 Feb 2010

FDA issues Complete Response Letter for Horizant in treatment of RLS

GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).

18 Feb 2010

Ibuprofen may reduce risk of Parkinson's disease, says study

New research shows people who regularly take ibuprofen may reduce their risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

18 Feb 2010

NMT Medical completes private placement of common stock and warrants for $5.8M

NMT Medical, Inc. today announced that it has completed a private placement of its common stock and warrants to purchase additional shares of common stock to existing and new stockholders for aggregate proceeds of approximately $5.8 million.

17 Feb 2010

Migraine is seen more frequently in women with MS than those without: Study

Migraine is seen more frequently in women with multiple sclerosis (MS) than those without, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

17 Feb 2010

MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial

MAP Pharmaceuticals, Inc. today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

16 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Botulinum injection used for cosmetic purposes may reduce migraine headaches

A preliminary study suggests the same type of botulinum injection used for cosmetic purposes may be associated with reduced frequency of migraine headaches that are described as crushing, vicelike or eye-popping (ocular), but not pain that is experienced as a buildup of pressure inside the head, according to a report in the February issue of Archives of Dermatology, one of the JAMA/Archives journals.

15 Feb 2010

Southridge provide equity capital financing for PuraMed BioScience

Southridge LLC, an investment firm providing capital to publicly listed companies, is pleased to announce that its affiliated fund has closed a private equity agreement for up to $7.5 million in equity financing with PuraMed BioScience.

12 Feb 2010

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has begun distributing and selling Cobroxin through mass food and drug retail chains in the Northeast, Southeast, Middle Atlantic and Midwest regions.

12 Feb 2010

NMT Medical announces preliminary unaudited figures for fiscal 2009

NMT Medical, Inc. today announced that it expects to report full year 2009 revenues of approximately $13.2 million – within the Company’s previously-announced guidance range of $13 million to $14 million.

11 Feb 2010

Headache is a common and persistent symptom in people exposed to dust at World Trade Center

Workers and residents exposed to dust and fumes caused by the collapse of the World Trade Center on September 11, 2001 frequently reported headache years later, according to research released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

11 Feb 2010

Migraine sufferers face increase risk of heart attack, says study

People with migraine may be at an increased risk of heart attack and other risk factors for heart disease, according to a study published in the February 10, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

11 Feb 2010

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

10 Feb 2010

Drinking milk during pregnancy can protect baby against multiple sclerosis

Drinking milk during pregnancy may help reduce your baby's chances of developing multiple sclerosis (MS) as an adult, according to a preliminary study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

10 Feb 2010